Copyright
©2014 Baishideng Publishing Group Inc.
World J Hepatol. Jul 27, 2014; 6(7): 520-526
Published online Jul 27, 2014. doi: 10.4254/wjh.v6.i7.520
Published online Jul 27, 2014. doi: 10.4254/wjh.v6.i7.520
Table 2 Percentage of patients who responded in terms of rapid virologic response, early virologic response, end of the treatment virologic response, and sustained virologic response in genotypes 1, 3 and 4 by intention-to-treat analysis
Parameter | Genotype 1 | Genotype 31 | Genotype 4 |
(n = 27) | (n = 56) | (n = 17) | |
RVR | 25.9% | 71.4% | 58.8% |
EVR | 74.1% | 87.5% | 88.2% |
ETVR | 59.2% | 78.6% | 70.5% |
SVR | 44.4% | 64.3% | 52.9% |
- Citation: Rao P, Koshy A, Philip J, Premaletha N, Varghese J, Narayanasamy K, Mohindra S, Pai NV, Agarwal MK, Konar A, Vora HB. Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C. World J Hepatol 2014; 6(7): 520-526
- URL: https://www.wjgnet.com/1948-5182/full/v6/i7/520.htm
- DOI: https://dx.doi.org/10.4254/wjh.v6.i7.520